Targeting cannabinoid receptors for obesity faces safety hurdles
Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders.
AI Summary
Obesity is linked to insulin resistance and other serious metabolic problems. This review examines whether blocking cannabinoid-1 receptors (CB1R) outside the brain could improve obesity and related disorders while avoiding the psychiatric toxicity associated with centrally acting drugs such as rimonabant. The approach targets the bodyβs endocannabinoid system, but it concerns medicines that alter cannabinoid signalingβnot the effects of using cannabis or THC products.
The review finds that peripherally restricted CB1R antagonists remain promising in theory but face important safety and effectiveness challenges. Phase 2 data for monlunabant showed dose-dependent psychiatric adverse events and high treatment-discontinuation rates, while the antibody-based drug nimacimab produced only marginal efficacy. The authors conclude that future progress will depend on rigorous long-term safety testing, more selective CB1R pharmacology, and combination strategies involving incretin-based therapies.
π‘ Key Findings
π
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronicβ¦
Explore More Research
Stay informed about the latest cannabis science.